Keywords: xenova/gsk, th-hsv, ph, ii, trial, disappoints, uk

Xenova/GSK TH-HSV Ph II trial disappoints

Article | 12 October 2001

Print This

UK company Xenova says that results from the Phase II clinical efficacytrial of TA-HSV (a therapeutic vaccine designed for the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in